Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421560 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
A Phase 1 study of Refractory Cancer and Primary Central Nervous System Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 4
- Study locations
NCT04421560 is a Phase 1 study of Refractory Cancer and Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 37 participants, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT04421560, a Phase 1 study of Refractory Cancer and Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Rituximab
- DRUG Ibrutinib
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2027-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04421560
The ClinicalTrials.gov registry entry for NCT04421560 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04421560 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04421560 about?
NCT04421560 is a clinical study titled "Pembrolizumab, Ibrutinib and Rituximab in PCNSL". This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)
What is the current status of trial NCT04421560?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-08-01. Estimated completion is 2027-01-05.
What conditions does trial NCT04421560 study?
This clinical trial studies the following conditions: Refractory Cancer, Primary Central Nervous System Lymphoma, Relapsed Cancer, Recurrent Cancer.
What interventions are being tested in trial NCT04421560?
The interventions under investigation include: Pembrolizumab (DRUG), Rituximab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT04421560?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04421560 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Cancer
All registered trials for this condition
Primary Central Nervous System Lymphoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.